3results about How to "Good tissue permeability" patented technology

The application belongs to the technical field of biological medicine, and particularly relates to a polypeptide degradation agent for targeted degradation of CD26 and a preparation method and application thereof. The polypeptide degradation agent is obtained after coupling of a tetrapeptide and lenalidomide. The amino acid sequence of the tetrapeptide is any one of SEQ ID NO. 1 and SEQ ID NO. 2. The polypeptide degradation agent can specifically target and degrade DPP4, i.e. CD26, but cannot degrade DPP4 isozymes such as DPP7, DPP8 and DPP9, and thus has high selectivity. In addition, the polypeptide degradation agent has small molecular weight, one end is a natural short peptide, has good tissue compatibility, can quickly degrade target proteins in 6 hours, and thus has good tissue permeability.

The application provides a method for constructing a double-signal sensing platform based on a non-copper nanometer enzyme AuPt@PBA@L-Pd and application, and a multifunctional nanometer composite material AuPt@L-Pd@PBA (hereinafter referred to as APL) with the effects of an oxidase-like enzyme, a peroxidase-like enzyme and a laccase-like enzyme is prepared. The composite nanometer enzyme has a regular cubic morphology, takes PBA as a base material, loads L-Pd through an amide bond, simultaneously collects the advantages of the MOF material PBA and L-Pd, has multiple enzyme-like effects, and can catalyze different chromogenic substrates. The AuNPs and PtNPs on the surface of APL not only provide good binding sites for antibodies, but also successfully prepare a biological composite probe Ab2@APL, further amplify the sensing signal, and improve the sensitivity of the sensing platform. It is worth mentioning that APL has the effect of a laccase-like enzyme, but does not contain copper ions, and further improves the biocompatibility. Based on the high catalytic activity and multifunctional nanometer enzyme Ab2@APL, a multi-signal sensing platform can be constructed, and the application prospect in more fields is wider.

This invention provides an aptamer targeting the growth hormone receptor and its uses, the nucleotide sequence of which is shown in SEQ ID NO.1 or SEQ ID NO.2. This invention utilizes a modified SELEX technique to perform multiple rounds of screening targeting recombinant GHR protein, obtaining specific nucleic acid aptamers with high affinity for GHR (KD values ​​at the micromolar level). In vivo distribution experiments show that the fluorescently labeled aptamer can efficiently and specifically accumulate in white adipose tissue (including inguinal and gonadal fat) at the in vivo level, exhibiting excellent tissue targeting. The nucleic acid aptamer and its derivatives of this invention can be used to prepare drugs or diagnostic reagents targeting adipose tissue, for example, for the prevention or treatment of metabolic diseases such as obesity, type 2 diabetes, fatty liver, hyperlipidemia, or cardiovascular disease.